Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

Condition(s) studied

Study summary

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.

During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.

No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Eligibility

Primary outcome measure(s)

• Local tumor control — 6 months, 1 year, 2 years, 3 years
  Local tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.

Trial sites (3)

Other trials for the same condition